Vericiguat alleviates ventricular remodeling and arrhythmias in mouse models of myocardial infarction via CaMKII signaling

Chen, Tao; Kong, Bin; Shuai, Wei; Gong, Yang; Zhang, Jingjing; Huang, He

doi:10.1016/j.lfs.2023.122184

Cited by 5 publications

(1 citation statement)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, data specifically concerning SCD were not provided [ 113 ]. In pre-clinical mouse models, Vericiguat demonstrated the potential for anti-arrhythmic properties through favorable effects on ventricular remodeling and ionic currents, notably by inhibiting CaMKII [ 114 ]. Further investigations are warranted to validate these preliminary findings on its anti-arrhythmic properties.…”

Section: Emerging Horizons In Heart Failure Treatmentmentioning

confidence: 99%

Anti-Arrhythmic Effects of Heart Failure Guideline-Directed Medical Therapy and Their Role in the Prevention of Sudden Cardiac Death: From Beta-Blockers to Sodium-Glucose Cotransporter 2 Inhibitors and Beyond

Zaher,

Della Rocca,

Pannone

et al. 2024

JCM

View full text Add to dashboard Cite

Sudden cardiac death (SCD) accounts for a substantial proportion of mortality in heart failure with reduced ejection fraction (HFrEF), frequently triggered by ventricular arrhythmias (VA). This review aims to analyze the pathophysiological mechanisms underlying VA and SCD in HFrEF and evaluate the effectiveness of guideline-directed medical therapy (GDMT) in reducing SCD. Beta-blockers, angiotensin receptor–neprilysin inhibitors, and mineralocorticoid receptor antagonists have shown significant efficacy in reducing SCD risk. While angiotensin-converting enzyme inhibitors and angiotensin receptor blockers exert beneficial impacts on the renin-angiotensin-aldosterone system, their direct role in SCD prevention remains less clear. Emerging treatments like sodium-glucose cotransporter 2 inhibitors show promise but necessitate further research for conclusive evidence. The favorable outcomes of those molecules on VA are notably attributable to sympathetic nervous system modulation, structural remodeling attenuation, and ion channel stabilization. A multidimensional pharmacological approach targeting those pathophysiological mechanisms offers a complete and synergy approach to reducing SCD risk, thereby highlighting the importance of optimizing GDMT for HFrEF. The current landscape of HFrEF pharmacotherapy is evolving, with ongoing research needed to clarify the full extent of the anti-arrhythmic benefits offered by both existing and new treatments.

show abstract

Section: Emerging Horizons In Heart Failure Treatmentmentioning

confidence: 99%